BRAF and melanoma: Here we used the mitogen-activated protein kinase (MAPK) pathway inhibitors vemurafenib (PLX4032) (mutant BRAF inhibitor, mBRAFi) and trametinib (MEK inhibitor, MEKi) as these are frontline therapeutics in the management of melanoma in the clinic.